BR112023026076A2 - Terapia combinada de radioimunoconjugados e inibidores de checkpoint - Google Patents

Terapia combinada de radioimunoconjugados e inibidores de checkpoint

Info

Publication number
BR112023026076A2
BR112023026076A2 BR112023026076A BR112023026076A BR112023026076A2 BR 112023026076 A2 BR112023026076 A2 BR 112023026076A2 BR 112023026076 A BR112023026076 A BR 112023026076A BR 112023026076 A BR112023026076 A BR 112023026076A BR 112023026076 A2 BR112023026076 A2 BR 112023026076A2
Authority
BR
Brazil
Prior art keywords
radioimmunoconjugates
checkpoint inhibitors
combined therapy
combined
therapy
Prior art date
Application number
BR112023026076A
Other languages
English (en)
Portuguese (pt)
Inventor
Steven Burak Eric
Fitzmaurice Valliant John
Julie Metcalf
Meiduo Hu
Natalie Grinshtein
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of BR112023026076A2 publication Critical patent/BR112023026076A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112023026076A 2021-06-11 2022-06-10 Terapia combinada de radioimunoconjugados e inibidores de checkpoint BR112023026076A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163209736P 2021-06-11 2021-06-11
PCT/US2022/033058 WO2022261467A1 (en) 2021-06-11 2022-06-10 Radioimmunoconjugates and checkpoint inhibitor combination therapy

Publications (1)

Publication Number Publication Date
BR112023026076A2 true BR112023026076A2 (pt) 2024-03-05

Family

ID=84426354

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023026076A BR112023026076A2 (pt) 2021-06-11 2022-06-10 Terapia combinada de radioimunoconjugados e inibidores de checkpoint

Country Status (13)

Country Link
US (1) US20240285818A1 (cg-RX-API-DMAC7.html)
EP (1) EP4351662A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024521418A (cg-RX-API-DMAC7.html)
KR (1) KR20240021227A (cg-RX-API-DMAC7.html)
CN (1) CN117794585A (cg-RX-API-DMAC7.html)
AR (1) AR126128A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022291150A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023026076A2 (cg-RX-API-DMAC7.html)
CA (1) CA3222948A1 (cg-RX-API-DMAC7.html)
IL (1) IL309243A (cg-RX-API-DMAC7.html)
MX (1) MX2023014778A (cg-RX-API-DMAC7.html)
TW (1) TW202317204A (cg-RX-API-DMAC7.html)
WO (1) WO2022261467A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3265502A1 (en) * 2022-08-22 2024-02-29 Abdera Therapeutics Inc. DOTA ANTIBODY CONJUGATES VHH
CN120897762A (zh) * 2023-04-12 2025-11-04 康奈尔大学 用于治疗癌症的放射治疗缀合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7922998B2 (en) * 2003-01-13 2011-04-12 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
KR20210099073A (ko) * 2018-12-03 2021-08-11 퓨전 파마슈티칼즈 인크. 방사성면역접합체와 체크포인트 억제제의 조합 요법

Also Published As

Publication number Publication date
TW202317204A (zh) 2023-05-01
EP4351662A4 (en) 2026-07-01
CN117794585A (zh) 2024-03-29
MX2023014778A (es) 2024-01-15
KR20240021227A (ko) 2024-02-16
CA3222948A1 (en) 2022-12-15
JP2024521418A (ja) 2024-05-31
US20240285818A1 (en) 2024-08-29
WO2022261467A1 (en) 2022-12-15
WO2022261467A9 (en) 2023-05-04
IL309243A (en) 2024-02-01
AU2022291150A1 (en) 2023-12-21
AR126128A1 (es) 2023-09-13
EP4351662A1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
CL2021001433A1 (es) Terapia de combinación de radioinmunoconjugados con inhibidor del punto de control
PT3883579T (pt) Terapia de combinação incluindo um inibidor de kras-g12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cancros
JOP20220008A1 (ar) مثبطات parp1
MX2023009521A (es) Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d.
MX2019012032A (es) Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3).
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
MX2021013317A (es) Terapias de combinacion que comprenden inhibidores de apremilast y tyk2.
MX384438B (es) Compuestos farmacéuticos.
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
MX387283B (es) Tratamiento del cancer con tg02.
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
BR112022008191A2 (pt) Terapia com antagonista de lag-3 para melanoma
PE20221410A1 (es) Composicion farmaceutica para el tratamiento de cancer, que comprende inhibidor de punto de control inmunologico y proteina de fusion que incluye proteina il-2 y proteina cd80
BR112019019261A2 (pt) Terapias de combinação para o tratamento de câncer de mama
WO2022261467A9 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
JOP20250311A1 (ar) مثبطات tyk2 وتركيبات وطرق لها
MX390751B (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
MX2020011912A (es) Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc).
MX2020007375A (es) Terapias de combinacion para el tratamiento de carcinoma hepatocelular.
MX2024009317A (es) Radiofarmacos dirigidos a ntsr1 y terapia de combinacion de inhibidores punto de control.
MX2022003628A (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.
MX2023005072A (es) Bloqueo de cd47 y terapias combinadas de los mismos para reducir la inflamacion vascular.
BR112022009522A2 (pt) Métodos de administração de voxelotor
PH12022551172A1 (en) Anti-pcsk9 antibody and use thereof